The product works by inducing differentiation and apoptosis of atypical promyelocytes, effectively controlling disease progression. Recommended for patients diagnosed with acute promyelocytic leukaemia, including as part of combination therapy.
Acute promyelocytic leukaemia (APL)
Taken orally as prescribed by a physician, usually twice daily with food. Dosage is individualised.
Contraindications:
Side Effects: